[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced on 25 September 2025 the purchase of 3,251,858 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. The purchases included 3,101,999 shares executed on 24 September 2025 on the London Stock Exchange CBOE (UK)/CXE at an average price of £330.4723 per share as shown in the trade breakdown. The Company intends to hold the acquired shares as treasury shares. After settlement the registered share capital is 8,952,353,648 ordinary shares, of which 36,589,403 are treasury shares, leaving 8,915,764,245 ordinary shares with voting rights for FCA disclosure guidance purposes. A full breakdown of individual trades is available at the provided RNS link and on the Company website.

Positive

• 3,251,858 shares repurchased under the second tranche of the buyback programme, showing active capital return execution
• Purchased shares will be held as treasury shares, providing the company flexibility for future capital management
• Detailed trade breakdown provided and posted on the Company website and RNS, meeting Market Abuse Regulation disclosure requirements

Negative

• None.

Insights

Equity Capital Markets Analyst

TL;DR Haleon executed a material tranche of its buyback, reducing free float and increasing treasury holdings.

The announcement documents the purchase of 3.25 million ordinary shares under the second tranche of the buyback. The company will hold the shares as treasury stock, which reduces the number of shares outstanding with voting rights to 8,915,764,245. The disclosure includes a trade-level breakdown consistent with Market Abuse Regulation requirements and provides the average execution price for the reported trades. For shareholders and regulators, the key facts are the quantity repurchased, the treasury intent, and the updated share counts used for FCA notification thresholds.

Corporate Governance Specialist

TL;DR Buyback is formally disclosed with required regulatory detail and updates to voting-share counts.

The filing meets disclosure obligations by stating the number of shares bought, the intention to hold as treasury shares, and the post-settlement registered capital and treasury holdings. It highlights the updated voting-share figure that investors must use for FCA notification thresholds. The inclusion of a public trade breakdown link aligns with transparency expectations under the Market Abuse Regulation as applied in the UK.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	25 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

25 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 3,251,858 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	24 September 2025	24 September 2025	24 September 2025
Number of Shares purchased:	3,101,999	149,859	-
Highest price paid per Share (p):	332.4000	332.3000	-
Lowest price paid per Share (p):	327.6000	327.7000	-
Volume weighted average price paid per Share (p):	330.4723	330.2795	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 36,589,403 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,915,764,245 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7050A_1-2025-9-24.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 25, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLN) announce in the 6-K dated 25 September 2025?

Haleon announced the purchase of 3,251,858 ordinary shares under the second tranche of its buyback programme and that the shares will be held as treasury shares.

How many Haleon shares are held as treasury shares after this purchase?

After settlement, 36,589,403 ordinary shares are held as treasury shares.

What is the number of Haleon ordinary shares with voting rights after the buyback?

The number of ordinary shares with voting rights is 8,915,764,245 as stated in the filing.

Where can I find a full breakdown of the individual trades for the Haleon buyback?

A full breakdown is available at the RNS link provided in the filing: http://www.rns-pdf.londonstockexchange.com/rns/7050A_1-2025-9-24.pdf and on www.haleon.com/investors.

What price was reported for the executed trades in the announcement?

The filing reports an average trade execution price of £330.4723 for the referenced trades on 24 September 2025.